The new share buyback program comes in addition to the $6.4 billion remaining under current authorization.
The quarterly dividend was raised from 32 cents to 34 cents per share, which equates to an annual dividend of $1.36 per share. The increased dividend will be payable to shareholders Mar. 1, 2018.
More articles on supply chain:
FDA cracks down on homeopathic drugs
Teva Pharmaceuticals to cut more than 25% of workforce, consolidate US sites
Two months after approval, Gilead’s ‘breakthrough’ cancer drug given to just a handful of patients
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
